Breakthrough Achievement: HeLuo XinTu's iPSC-Derived Universal Platelets Demonstrate Clinical Feasibility in First-in-Human Study
Renerval Therapeutics
Cell Therapy Technology Developer
April 24, 2025
eMedClub News
In April 2025, Renerval Therapeutics announced the latest data from an investigator-initiated clinical study (IIT) for its self-developed universal artificial regenerated platelet candidate product RBT101.RBT101 Demonstrates Good Safety and Quantifiable Efficacy Signals in Humans.
Public information shows that this is the world's first clinical case demonstrating the clinical feasibility of universal artificial regenerated platelets.
Tackling the "Blood Shortage" Challenge: Artificially Regenerated Platelets Show Clinical Value
As of the date, the clinical data since the completion of the world's first infusion in March 2025 in this IIT study shows:
In terms of safety：RBT101 demonstrated good safety in humans, with no DLT events or serious adverse events occurring.
Efficacy Trend：After the infusion of RBT101, the platelet count in subjects rebounded and did not show a significant decrease during the plateau phase of the efficacy curve.
The dose will be further increased and the clinical sample size expanded to further verify the effectiveness of the artificially regenerated platelet RBT101.
Science Illuminates Life, Innovation Reshapes the Future
The successful clinical infusion of RBT101 has achieved a breakthrough from "0" to "1" in China's artificial blood field.Marking its great potential to become the first human-derived platelet substitute product in China.`, which is expected to bring revolutionary treatment options for patients with thrombocytopenia.`
Renerval Therapeutics will continue to deepen its focus on the cell therapy field, with a complete layout of the "artificial blood system."Advance Transfusion Medicine into a New Era of "Accessibility, Controllability, and Affordability"。
AboutRenerval Therapeutics
Renerval Therapeutics was founded in 2021. The entrepreneurial team is led by returning scholars from the Massachusetts Institute of Technology (USA) and the University of Cambridge (UK). It is a high-tech innovative enterprise focused on iPSC directed differentiation, gene editing, large-scale cell product preparation, and cell therapy technology development.
Renerval Therapeutics addresses core challenges and clinical needs in the field of regenerative medicine through years of innovative cell-directed differentiation technology in the iPSC domain. The company is committed to building an artificial blood production platform while simultaneously establishing a world-leading regenerative medicine cell product development system. Renerval's R&D team consists of young scholars from renowned universities and research institutions both in China and abroad, as well as outstanding talents with years of industry experience. The team has extensive research and industrial experience in stem cells and translational medicine.
References:
1.https://mp.weixin.qq.com/s/RNFgV7j1X0B4aSDl6VvW3w
Exciting Live Broadcast Preview
Long press to scan the QR code and participate immediately ↓
Swipe up to view
In Partnership with 医麦客 IBI EXPO 2026
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
DianDian "Share”、“Like" and "In View", charge me up a bit~"